// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Slow Motion Analysis of Repetitive Tapping (SMART) test: measuring of bradykinesia in recently diagnosed Parkinson’s disease and idiopathic anosmia

C. Simonet - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Speaking with your hands in Parkinson’s: Investigating the rate and precision of co-speech gestures

E. Poliakoff - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Striatal dopaminergic loss in early clinically unilateral Parkinson’s disease: a systematic review

N. Heng - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

Dopamine hydrochloride

Subjective cognitive complaints assessed with the cognitive domain of the Non-Motor Symptoms Scale predict longitudinal cognitive trajectory in people with Parkinson’s disease with normal cognition

L. Batzu - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Terminal Choking in Parkinson’s Disease

F. Herbert - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

The association between antipsychotic-induced akathisia and suicidality: a systematic review

A. Kalniunas - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Akathisia

N/A

The effect of deep brain stimulation on impulse control related disorders in Parkinson’s disease – a retrospective review of 137 patients

H. Shepherd - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

Levodopa

The EON (Elderly patients on ONgentys) study in Parkinson’s disease: design and rationale of a prospective non-interventional trial

V. Dostal - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

The experiences of treatment burden in people with Parkinson’s (PwP) and their caregivers: a systematic review of qualitative studies

QY. Tan - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

The feasibility of using an internet-based cognitive behavioural therapy programme as an intervention for people diagnosed with adult-onset, focal, isolated, idiopathic cervical dystonia

M. Wadon - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Cervical dystonia

N/A

The Gastrointestinal Dysfunction Scale – Parkinson’s Disease (GIDS-PD): a new tool to assess gastrointestinal dysfunction in Parkinson’s Disease

M. Camacho - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

The influence of pain on falls in newly diagnosed Parkinson’s disease

J. Naisby - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

The OCEAN (OpiCapone Effect on motor fluctuations and associated pAiN) study in Parkinson’s disease: design and rationale of a randomized double-blind placebo-controlled trial

K. Chaudhuri - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

Levodopa

The prevalence of sarcopenia in Parkinson’s disease and related disorders

A. Hart - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

The PRIME Qual study protocol: A qualitative exploration of the experiences of patients, caregivers/families and hospital/intervention staff of the PRIME Randomised Controlled Trial

H. Brant - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

The role of community engagement and involvement in Parkinson’s disease research: a case study from Africa

N. Fothergill-Misbah - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

To Prescribe or Not to Prescribe: The impact of Parkinson’s nurse prescribers

A. Hand - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Using a Dopamine Genetic Risk Score to Predict Impulse Control Behaviours for Parkinson’s Disease Patients

A. Hall - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

Dopamine hydrochloride

Using smartphone data to infer social behaviour in Parkinson’s: proof of principle and the impact of COVID19

H. Zhang - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Visuo-cognitive training in Parkinson’s disease: Protocol for a randomised cross-over trial.

J. Das - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Copyright © 2026. QuantiNova All rights reserved